ENTITY
Lonza Group

Lonza Group (LONN SE)

17
Analysis
Health Care • Switzerland
Lonza is a global partner to the pharmaceutical, biotech and nutrition markets. The company works with healthcare customers to develop, manufacture and commercialize medical treatments and technologies to treat patients against a range of diseases. Founded in the Swiss Alps, Lonza now operates across Europe, North America, South America, Asia and Oceania.
more
bullish•SK Bioscience
•25 Feb 2021 07:47

SK Bioscience IPO - Valuation Analysis

We believe that SK Bioscience's market cap value could be about 11.5 trillion won or 149,000 won per share which would represent 129% higher than...

Logo
426 Views
Share
bullish•SK Bioscience
•07 Feb 2021 02:23

SK Bioscience IPO Preview - Biggest IPO in Korea in 1Q 2021

SK Bioscience is getting ready to complete its IPO in Korea in March. SK Bioscience will be the biggest IPO in Korea so far this year in 2021. The...

Logo
595 Views
Share
bullish•Lonza Group AG
•17 Jul 2020 10:48

Lonza: A Bellwether Biopharma Focused CDMO | At Inflection Point, To Benefit from Ongoing Capex

Over the next few weeks/months, we will be initiating coverage on a few key players in the Global CDMO space, where we see interesting growth...

Logo
595 Views
Share
•29 Jan 2020 07:51

EM Pullback Opportunity

Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point,...

Logo
544 Views
Share
bullish•MSCI World Index
•09 Sep 2019 08:22

Global Equity Strategy: Guarded Optimism

Global equities (MSCI ACWI) are decisively breaking above 1-month resistance on US-China trade war optimism, incrementally improving the technical...

Logo
484 Views
Share
x